Companies in #Antibody Discovery
Found 3 companies operating in this sector.
Beijing-headquartered global biotechnology company (SSE: 688796, HKEX: 02315) providing integrated antibody drug development solutions through proprietary gene-editing platforms and RenMab/RenNano antibody discovery engines.
OmniAb licenses antibody discovery technology to pharmaceutical, biotech, and academic partners, using engineered transgenic animals (OmniRat, OmniChicken, OmniMouse), bispecific platforms (OmniFlic, OmniClic), cow-inspired OmniTaur antibodies, the OmnidAb single-domain platform, and the OmniDeep suite of in-silico AI/ML discovery tools. Spun out of Ligand Pharmaceuticals in 2022 and headquartered in Emeryville, California, the company generates revenue through partnered milestone payments and license fees; Q2 2026 revenue more than tripled year over year as partner milestones accelerated, and it raised its full-year 2026 revenue and year-end cash outlook.
Twist Bioscience Corporation is a synthetic biology company that manufactures synthetic DNA at scale on a proprietary silicon-based synthesis platform. Its product lines include synthetic genes, oligo pools, variant libraries, antibody discovery libraries, next-generation sequencing target enrichment panels and biopharma drug-discovery services, sold into healthcare, industrial chemicals, agriculture and academic research markets. The company was founded in 2013 and is headquartered in South San Francisco, California. Its discovery-data offering supplies machine-learning-ready small-molecule and antibody developability data to pharmaceutical partners, including an October 2026 agreement with Eli Lilly's TuneLab network.